In Situ Immune Parameters and Their Prognostic Role on the Survival of Patients With Glioblastoma
Clinical trial NCT03481231 · COMPLETED
Trial details
- NCT number
- NCT03481231
- Sponsor
- Centre Georges Francois Leclerc
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2020-09-13
- Primary completion
- 2024-09-14
- Enrollment
- 160
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.